Zuoli Pharmaceutical

Zuoli Pharmaceutical (佐力药业) is identified in the supplied material as a traditional Chinese medicine brand. Its name and supplied website identify it as a commercial pharmaceutical entity, rather than a non-commercial namesake. The evidence provided does not establish its precise legal name, founding date, headquarters, ownership, listing status, leadership, or operating markets, so those details are not asserted here. The supplied evidence associates the brand with Chinese patent medicines and traditional Chinese medicine. It does not name specific products, formulations, therapeutic categories, or sales channels. Accordingly, this dossier describes Zuoli at the level supported by the available material and does not attribute particular offerings or corporate milestones to it.

The supplied material identifies Zuoli Pharmaceutical as a traditional Chinese medicine brand but provides no dated information about its establishment, product launches, corporate changes, or expansion. Its history therefore cannot be reliably narrated from the available evidence. The supplied website is a potential source for further verification, but no website content was included in the evidence.

A traditional Chinese medicine brand; the supplied evidence does not specify its market positioning or product portfolio.

• Traditional Chinese medicine (中成药) products

  Zuoli Pharmaceutical is a Chinese brand in the traditional Chinese medicine (中成药) sector, offering TCM-based medicines.

• Unconfirmed

  Chen Huan sues Zoli Pharmaceutical over equity transfer payment[2]陈欢就股权转让款纠纷起诉佐力药业sc.stock.cnfol.com

  Chen Huan sued Zoli Pharmaceutical over a contract dispute, seeking equity-transfer payments and late-payment damages totaling more than RMB 100 million. The case had been accepted by the court but had not yet gone to trial, according to the report.

• 2020-08-05

  Chen Huan files contract lawsuit against Zuoli Pharmaceutical[3]陈欢起诉佐力药业合同纠纷finance.sina.com.cn

  Reported: 2020-08-24

  Chen Huan sued Zuoli Pharmaceutical over a contract dispute, seeking 77.979 million yuan in equity-transfer payment and 24.3294 million yuan in liquidated damages. The case had been accepted by the court and had not yet gone to trial.

• 2019-10-20

  Huadong Medicine and Zuoli Pharmaceutical terminate proposed stake acquisition[4]华东医药终止拟收购佐力药业股权finance.sina.com.cn

  Reported: 2019-10-20

  Huadong Medicine disclosed that it had terminated its proposed acquisition of an 18.6% stake in Zuoli Pharmaceutical after the parties were unable to agree on a solution and agreed to end the letter of intent.

1. 1佐力药业官网zuoli.com
2. 2陈欢就股权转让款纠纷起诉佐力药业sc.stock.cnfol.com
3. 3陈欢起诉佐力药业合同纠纷finance.sina.com.cn
4. 4华东医药终止拟收购佐力药业股权finance.sina.com.cn
5. 5华东医药终止收购佐力药业18.6％股权 两难收购止于同业竞争finance.sina.com.cn
6. 6华东医药终止收购佐力药业股权 高溢价曾备受质疑finance.sina.com.cn
7. 7溢价收购因同业竞争被终止 华东医药布局中药慢病受阻finance.sina.com.cn
8. 8佐力药业爽约背后：标的亏损收购无业绩承诺 资金趋紧finance.sina.com.cn